Regulatory & Safety Aspects of Cell & Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

    Related Conference of Regulatory & Safety Aspects of Cell & Gene Therapy

    April 03-04, 2023

    International Conference on Aging and Gerontology

    Rome, Aland Islands
    May 03-04, 2023

    16th World Congress on Stem Cell Research

    Paris, France
    May 03-04, 2023

    Global Conference on Cell and Gene Therapy

    Paris, France
    June 08-09, 2023

    10th World Congress on Epigenetics and Chromosome

    Valencia, Spain
    August 21-22, 2023

    6th Annual Conference on Stem Cell and Regenerative Medicine

    Frankfurt, Germany
    September 25-26, 2023

    19th Global Summit on Stem Cell & Regenerative Medicine

    Zurich, Switzerland
    October 19-20, 2023

    5th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada
    December 07-08, 2023

    17th International Conference on Genomics & Pharmacogenomics

    San Francisco, USA

    Regulatory & Safety Aspects of Cell & Gene Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in